ATE266034T1 - Gastro-spezifische prodrugs - Google Patents
Gastro-spezifische prodrugsInfo
- Publication number
- ATE266034T1 ATE266034T1 AT01909258T AT01909258T ATE266034T1 AT E266034 T1 ATE266034 T1 AT E266034T1 AT 01909258 T AT01909258 T AT 01909258T AT 01909258 T AT01909258 T AT 01909258T AT E266034 T1 ATE266034 T1 AT E266034T1
- Authority
- AT
- Austria
- Prior art keywords
- disclosed
- hydrophilic group
- gastro
- awh
- drug
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title abstract 3
- 239000000651 prodrug Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000007107 Stomach Ulcer Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 229920005862 polyol Polymers 0.000 abstract 1
- 150000003077 polyols Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/514,819 US6413945B1 (en) | 1997-04-04 | 2000-02-28 | Gastro-specific prodrugs |
| PCT/US2001/004960 WO2001064690A1 (en) | 2000-02-28 | 2001-02-16 | Gastro-specific prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE266034T1 true ATE266034T1 (de) | 2004-05-15 |
Family
ID=24048822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01909258T ATE266034T1 (de) | 2000-02-28 | 2001-02-16 | Gastro-spezifische prodrugs |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6413945B1 (de) |
| EP (1) | EP1261613B1 (de) |
| JP (1) | JP2003525301A (de) |
| AT (1) | ATE266034T1 (de) |
| AU (1) | AU2001237033A1 (de) |
| DE (1) | DE60103134T2 (de) |
| DK (1) | DK1261613T3 (de) |
| ES (1) | ES2215880T3 (de) |
| PT (1) | PT1261613E (de) |
| TR (1) | TR200401012T4 (de) |
| WO (1) | WO2001064690A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1744785A1 (de) * | 2004-04-30 | 2007-01-24 | Kopran Research Laboratories Limited | Hydroxyalkylderivate von biologischen wirkstoffen |
| US8945527B2 (en) * | 2008-04-25 | 2015-02-03 | The University Of North Carolina At Chapel Hill | Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates |
| US20110212986A1 (en) * | 2008-08-21 | 2011-09-01 | Health Research, Inc. | Anti-flavivirus therapeutic |
| US20130203675A1 (en) | 2010-09-16 | 2013-08-08 | Joseph M. DeSimone | Asymmetric biofunctional silyl monomers and particles thereof as prodrugs and delivery vehicles for pharmaceutical, chemical and biological agents |
| EP3204121B1 (de) | 2014-10-08 | 2019-06-19 | Epigenetics Pharma LLC | Silylierte 5-aza-pyrimidin- prodrugs als krebsmittel |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5055604A (en) * | 1990-04-17 | 1991-10-08 | G. D. Searle & Co. | Process for preparing prostaglandin analogs using organozirconium compounds |
| WO1992001477A1 (en) * | 1990-07-26 | 1992-02-06 | G.D. Searle & Co. | Polymeric drug delivery system |
| JPH08165301A (ja) * | 1994-12-15 | 1996-06-25 | Mitsubishi Chem Corp | 環状イヌロオリゴ糖のシリル化誘導体およびその製造方法 |
| US5618959A (en) * | 1995-03-10 | 1997-04-08 | Vivus Incorporated | Process for preparing prostaglandin E1, E2 and analogs thereof using furylcopper reagents |
| US6030959A (en) * | 1997-04-04 | 2000-02-29 | Monsanto Company | Gastro-specific prodrugs |
-
2000
- 2000-02-28 US US09/514,819 patent/US6413945B1/en not_active Expired - Fee Related
-
2001
- 2001-02-16 DE DE60103134T patent/DE60103134T2/de not_active Expired - Fee Related
- 2001-02-16 AU AU2001237033A patent/AU2001237033A1/en not_active Abandoned
- 2001-02-16 TR TR2004/01012T patent/TR200401012T4/xx unknown
- 2001-02-16 WO PCT/US2001/004960 patent/WO2001064690A1/en not_active Ceased
- 2001-02-16 PT PT01909258T patent/PT1261613E/pt unknown
- 2001-02-16 AT AT01909258T patent/ATE266034T1/de not_active IP Right Cessation
- 2001-02-16 DK DK01909258T patent/DK1261613T3/da active
- 2001-02-16 ES ES01909258T patent/ES2215880T3/es not_active Expired - Lifetime
- 2001-02-16 JP JP2001564186A patent/JP2003525301A/ja not_active Withdrawn
- 2001-02-16 EP EP01909258A patent/EP1261613B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1261613A1 (de) | 2002-12-04 |
| AU2001237033A1 (en) | 2001-09-12 |
| DK1261613T3 (da) | 2004-08-09 |
| DE60103134T2 (de) | 2005-04-28 |
| JP2003525301A (ja) | 2003-08-26 |
| PT1261613E (pt) | 2004-08-31 |
| US6413945B1 (en) | 2002-07-02 |
| WO2001064690A1 (en) | 2001-09-07 |
| TR200401012T4 (tr) | 2004-10-21 |
| DE60103134D1 (de) | 2004-06-09 |
| ES2215880T3 (es) | 2004-10-16 |
| EP1261613B1 (de) | 2004-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT810209E (pt) | Hidroxietilamino-sulfonamidas de alfa- e beta-aminoacidos uteis como inibidores de protease retroviral | |
| NO20015172L (no) | 1-metyl-erytromycin-derivater | |
| DE602005023782D1 (de) | Pyrrolidinderivate zur behandlung einer von der reninaktivität abhängigen krankheit | |
| AU667593B2 (en) | Inhibitors of HIV protease useful for the treatment of AIDS | |
| MY138466A (en) | Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
| ATE266034T1 (de) | Gastro-spezifische prodrugs | |
| WO2004033423A3 (en) | Anticancer compounds | |
| EP1627635A3 (de) | Benzothiazolium Verbindungen zur Verwendung in Methoden zur Hemmung der NO Produktion und von TNF alpha und zur Behandlung von Coronavirus Infektionen | |
| GR3022604T3 (en) | Inhibitors of hiv protease useful for the treatment of aids. | |
| IL153804A0 (en) | Tyrosine derivatives as phosphatase inhibitors | |
| BR0200536A (pt) | Compostos de sulfonilpiridazinana úteis como inibidores de aldose reductase | |
| HUT77135A (hu) | Eljárás I típusú allergiás betegségek megelőzésére és kezelésére alkalmazható gyógyszerkészítmények előállítására | |
| NZ517315A (en) | New derivatives of A-500359 | |
| EP1254907A4 (de) | Pyrrolopyridazin-verbindungen | |
| IL156140A0 (en) | Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence | |
| WO2005090320A3 (en) | Triazole derivatives and method of using the same to treat hiv infections | |
| AU2003267751A1 (en) | Use of epothilone derivatives for the treatment of hyperparathyroidism | |
| DE50104100D1 (de) | Verwendung spezieller verbindungen zur prophylaxe und therapie von hepatitis c | |
| AU2003216965A1 (en) | Compounds, particularly of urea derivatives or ester derivatives of haloacetamidobenzoic acid and use thereof for the treatment of parasitic diseases | |
| NO20013464L (no) | Anvendelse av 3-isoksazolidinoner og hydroksylaminsyrer for behandling av infeksjoner |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1261613 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |